NCCN funds two studies through collaboration with AstraZeneca to evaluate effectiveness of osimertinib

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Comprehensive Cancer Network Oncology Research Program has funded two investigators from NCCN member institutions through a collaborative scientific research relationship with AstraZeneca to further evaluate the clinical effectiveness of osimertinib in the treatment of epidermal growth factor receptor-positive non-small cell lung cancer.

The following studies were awarded funding through NCCN ORP:

  • Daniel Gomez, of MD Anderson Cancer Center, “Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR).”
  • Pasi Jänne, Dana-Farber/Brigham and Women’s Cancer Center, Massachusetts General Hospital Cancer Center, “A Phase II Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer.”

Submissions were peer reviewed by the NCCN Osimertinib Scientific Review Committee.

The funded concepts were selected based on several criteria, including scientific merit, existing data, and the types of studies necessary to further evaluate the efficacy ofosimertinib.

NCCN ORP draws upon the expertise of investigators at the NCCN member institutions and their affiliates to facilitate all phases of clinical research. This research is made possible by collaborations with pharmaceutical and biotechnology companies in order to advance therapeutic options for patients with cancer. To date, this research model has received more than $60 million in research grants and supported more than 140 studies.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login